Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly Expands Bio Capabilities | Contract Pharma

What are you searching for?

Sign in
Breaking News

Lilly Expands Bio Capabilities

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Eli Lilly and Co. completed the first phase of a $560 million expansion to its biotech complex in Indianapolis. The investment is part of a $1 billion effort to strengthen and build its biotech drug R&D capabilities. Lilly’s plans for the complex, announced in 2002, have since doubled in size to meet its pipeline of biopharma drugs. Approximately 30% of Lilly’s total drug portfolio are biopharma medicines in several therapeutic categories.

With the state-of-the-art bioproducts pilot manufacturing plant, the company aims to bring advanced biotech medicines to patients through more efficient, productive and dependable manufacturing processes. The company has also opened a research support facility that 700 scientists, engineers and support staff will relocate to.

“These investments reinforce Lilly’s position as a biotech leader,” said John Lechleiter, Ph.D., Lilly’s president and chief operating officer. “In tandem with our rich history of biotechnology, they give us a competitive advantage to discover, develop, and launch important new biotech therapies.”

The construction of the three buildings, along with Lilly’s acquisition of Applied Molecular Evolution in 2004, accounts for a total biotech capital investment of approximately $1 billion. “These investments, part of the company’s planned growth strategy in the area of biotechnology, prove that Lilly is confident in its future in biotech,” said Dr. Lechleiter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters